Triple positive APS

 Triple-positive APS refers to the highest-risk antibody profile in Antiphospholipid syndrome (APS).

What “triple positive” means

A patient is triple positive if all three are present on two separate tests ≥12 weeks apart:

Antibody type	What it targets
Lupus anticoagulant (LA)	Functional clotting interference assay
Anticardiolipin antibodies (aCL)	Phospholipid-binding proteins
Anti–β2 glycoprotein I (anti-β2GPI)	β2 glycoprotein I protein

Why it matters (key point)

Triple positivity = highest thrombotic risk profile in APS

Compared with single or double positivity:

• Much higher risk of venous thrombosis (DVT/PE)
• Higher risk of arterial thrombosis (stroke, MI)
• Higher risk of pregnancy complications
• Higher recurrence risk after first clot

Clinical associations

Patients often present with:

• Deep vein thrombosis
• Pulmonary embolism
• Stroke or TIA (especially young patients)
• Recurrent miscarriage / placental insufficiency
• Livedo reticularis (mottled skin pattern)

Diagnosis (criteria concept)

APS diagnosis requires:

• Clinical event (thrombosis or pregnancy morbidity)
  AND
• Persistent antiphospholipid antibodies (like triple positivity)

Management overview

If thrombosis has occurred:

• Long-term anticoagulation (usually warfarin, not DOACs in triple-positive patients)

Pregnancy:

• Low-dose aspirin + heparin (LMWH)

Important clinical pearl

• Triple-positive APS patients have higher recurrence on DOACs (e.g., rivaroxaban) → many guidelines recommend warfarin instead

One-line summary

Triple-positive APS = lupus anticoagulant + anticardiolipin + anti-β2GPI → highest-risk autoimmune clotting disorder profile.

If you want, I can give:

• a quick exam mnemonic
• or a DOAC vs warfarin evidence summary (TRAPS trial)